The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Am I reading the Holdings RNS correctly? Did Miton sell 11.6M shares last Thursday?
Global
I now understand why you attract abuse on here and are filtered by many posters. You call me “a flipper” and question my commitment (and integrity) as a LTH of Avacta but what is that skewed opinion based on please? What is it you think I’m not sure about?
“. . . its odd you hold 75,000 shares and not sure so you need Rich Ken and Myles to assure you.” Arrogant prick.
I would like to thank and acknowledge Richken for his informed and positive contributions to this BB. I found Avacta by seeing his Monika at the top of LSE’s “Most Recommended” posters and then reading his posts. I am showing a very healthy paper profit on the 75,000 shares I hold here and have him (and Miles McNulty) to thank for that. GLA LTH
Dylandopia
The Govt still have £4Bn in the pot to invest in tests. Plenty there for Avacta to share in when they are ready to roll out there life-changing, society-saving, transport-sector-saving, low-cost, best in class rapid POC LFD. I patiently and confidently await the relatively near term news.
“respective”? I meant repetitive lol
I still think Turner Pope’s use of “relatively near term” is the classiest example of the variations available in English language compared to today’s kids use of “laters”! Talking of language I’ve detected a touch of Quentin Tarantino in recent posts here. First we had Miles McN using “gargantuan” reminiscent of Elle’s cold delivery to snake-bitten Bud in Kill Bill and now Mia Wallace’s line “two shakes of a lamb’s tail” from Pulp Fiction. Excellent diversions from the usual respective comments on here. GLA LTH
Vegas22
No particular reason. Just part of Simplywallstreet’s usual Company profile to inform investors of the Board members credentials. Lots of info on that site - check it out.
This is impressive . . .
“ Prof. Alastair Smith Co-founded Avacta Group Plc in January 2004 and has been its Chief Executive Officer since 2005. Prof. Smith serves as the Chief Executive Officer of Avacta Ltd. He is a Professor of Molecular Biophysics, Head of the Molecular and Nanoscale Physics Group in the School of Physics and Astronomy and Director of the Interdisciplinary Institute of Molecular Biophysics. His early research focused on nonlinear optics and exciton dynamics in polymeric materials and liquid crystals. He took up a position at the University of Leeds as a Leverhulme Special Research Fellow in 1995. He became the founder and first Director of the Institute of Molecular Biophysics at Leeds University. He has served as chairman of Molecular Biophysics at Leeds University. Prof. Smith serves as a Director of Curidium Medica Limited. He serves as an Executive Director of Avacta Group Plc. He is a biophysicist of world renown. He has published over 70 articles since 1997. He holds a post-doctoral in the USA with renowned spectroscopist Professor Robin Hochstrasser at the University of Pennsylvania. Prof. Smith has a degree and PhD in Physics from Manchester University.”
We’ve had “soon”
We’ve had “mid-summer“
We’ve had “a couple of weeks”
But Turner Pope’s Note on Intugemen win The Ingenuity Award with their closing statement of “relatively near term” lol
JDT: I am suggesting finding out at home if you are virus-free or not before finding out at the airport (or other mass gathering venue) via their testing mechanism. I'd simply buy and keep a stock of our LFD's at home and use as and when to avoid inconvenience later.
If we are discussing the LFD as the testing device then I would test myself at home before setting off for the airport. Why wait til you get there only to find you're carrying the virus ?
https://www.collinsongroup.com/en-eur/test-on-arrival
For what it’s worth I’ve written to them urging them to prepare for the arrival of our LFD
Trump, when confronted with a chart showing surging infections, dismissed the data in a Fox News interview, telling anchor Chris Wallace that if the nation tested less there would be fewer cases. The U.S. hit a record 77,225 new cases on July 16, according to data from Johns Hopkins University.
“Chris, that’s because we have great testing, because we have the best testing in the world,” Trump told Wallace. “If we didn’t test, you wouldn’t be able to show that chart. If we tested half as much, those numbers would be down.”
God help us all!
New York Times article today reports more than 15,000 new cases of the coronavirus announced on Sunday in Florida, marking the highest single-day total of known cases in any state since the start of the pandemic.
Florida’s surge soared past the previous record, set in New York, of more than 12,000 cases in a day. That occurred in April, during the worst of the outbreak there, when testing was scarce. And Florida is reporting far fewer deaths than New York.
Florida also saw single-day records in the counties that include Florida’s largest cities, including Miami, Fort Lauderdale, Orlando, Fort Myers, West Palm Beach, Pensacola and Sarasota.
Florida has recorded more than 269,800 cases, with more than 4,200 total deaths, according to a New York Times database.
New York Times article today reports more than 15,000 new cases of the coronavirus announced on Sunday in Florida, marking the highest single-day total of known cases in any state since the start of the pandemic.
Florida’s surge soared past the previous record, set in New York, of more than 12,000 cases in a day. That occurred in April, during the worst of the outbreak there, when testing was scarce. And Florida is reporting far fewer deaths than New York.
Florida also saw single-day records in the counties that include Florida’s largest cities, including Miami, Fort Lauderdale, Orlando, Fort Myers, West Palm Beach, Pensacola and Sarasota.
Florida has recorded more than 269,800 cases, with more than 4,200 total deaths, according to a New York Times database.
According to Google Translate and to save other genuine holders wasting their time, this unattributable nonsense reads as follows:
“ Friday, absolutely massive news about Astra Zeneca, a big global pharmaceutical giant in bed with #novacyt in a new multi-billion dollar announcement to the British government”
Jonesrichard:
You say in your post
“ it will very very satisfying for genuine holders here to know that we are helping in these health areas whilst also making money at the same time.”
I hold 70,000 shares but I’m sorry I do not believe the cash I invested allows me to either claim or feel I am helping in these health areas. Avacta didn’t receive the funds I invested, that was simply liquidity for the market maker.
Missing/edited part of web site address is directors talk
www.*************.net/avacta-group-rapid-antigen-test-and-affimer-reagents-that-block-the-covid-19-virus-interview/
Alastair Smith joins ************* to discuss its latest positive update on its rapid antigen test and affimer blocking reagent. Alastair provides more details around the antigen test development with Cytiva, the next steps in the development plan and explains how some of the Affimer reagents that they have developed which block the interaction between the virus spike protein and a human cell receptor have now been shown to prevent infection of human cells in a model coronavirus system.
Avacta Group is developing novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and pre|CISION
™ tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients. The Company’s therapeutics development activities are based in Cambridge, UK.
The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal’s immune response, to generate new antibodies; poor specificity in many cases; large size and cost.